Abstract 506: ANJ810 is a highly selective novel MCL1 inhibitor with optimized in vivo clearance showing robust efficacy in preclinical solid and hematological tumor models

Ulrike Rauh, Todd R. Golub, Michael H. Serrano‐Wu et al.|Cancer Research|2023

Cited by 1